No Data
Catalyst Watch: Eyes on Electric Vehicle Deliveries, Retail Data and Housing Reads
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Springworks Therapeutics (SWTX)
Barclays Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
In 2025, US Biotech stocks are expected to rise significantly. jpmorgan's top pick is vertex pharmaceuticals (VRTX.US).
Vertex pharmaceuticals (Vertex) ranked first on the list of US biotechnology stock selections for 2025 released by jpmorgan.
No Data
